clinical trial · NCT05858645
Correction of Psoriatic T Cell Signatures by Deucravacitinib
University of California, San Francisco·phase4·recruiting·n = 25
Psoriasis Vulgarisdeucravacitinib
brief summary
This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the Tyrosine kinase 2 (TYK2) blocker, deucravacitinib.
started
Oct 1, 2023
primary completion
Jun 1, 2028
completion
Jun 1, 2028
last updated
Jun 4, 2026
detailed description
This is a one-arm, open-label study to examine the effect of deucravacitinib on cutaneous and blood immune cells of psoriatic patients. 25 subjects with moderate to severe psoriasis will be enrolled. Biopsy and blood samples will be collected before and during treatment and undergo molecular profiling to assess for deucravacitinib-corrected signatures.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol